Quinine‑Induced Hearing Loss
Overview
Quinine‑induced hearing loss is a form of ototoxicity—damage to the inner ear structures caused by exposure to the medication quinine. Quinine, originally derived from the bark of the cinchona tree, is most widely recognized for treating malaria and for off‑label use in managing nocturnal leg cramps. While effective for these indications, quinine can be toxic to the delicate hair cells of the cochlea and the auditory nerve, leading to temporary or permanent hearing impairment.
Who it affects: The condition can develop in anyone taking quinine, but the risk is higher in:
- Adults receiving high‑dose or prolonged therapy for malaria prophylaxis or treatment.
- Patients with pre‑existing kidney or liver disease (reduced drug clearance).
- Elderly individuals, who often have age‑related auditory vulnerability.
- People concomitantly using other ototoxic drugs (e.g., aminoglycoside antibiotics, loop diuretics).
Prevalence: Ototoxic adverse effects are reported in 2–6 % of patients who take quinine at therapeutic doses, with higher rates (up to 15 %) in those using high‑dose regimens for severe malaria. The exact incidence of permanent hearing loss is lower, estimated at 0.5–1 % of all quinine users, but may be under‑reported because mild symptoms often resolve spontaneously and go unnoticed.1,2
Symptoms
Symptoms can appear within hours to several days after starting quinine and may progress even after the drug is stopped. The pattern and severity differ among individuals.
Auditory symptoms
- Tinnitus – Ringing, buzzing, or hissing sounds in one or both ears.
- Hearing loss – Usually sensorineural, affecting high frequencies first; may be unilateral or bilateral.
- Ear fullness or pressure – A sensation of “blocked” ears.
- Distorted sound perception – Difficulty understanding speech, especially in noisy environments.
Associated systemic symptoms
- Dizziness or vertigo (can indicate vestibular involvement).
- Nausea, vomiting, or abdominal cramps (common quinine side effects that may coexist).
- Visual disturbances (rare but reported with high quinine levels).
Symptoms are often dose‑related; however, idiosyncratic reactions can cause severe toxicity at standard doses.
Causes and Risk Factors
Quinine’s ototoxicity stems from its interference with ion channels and mitochondrial function in cochlear hair cells. The drug impairs the potassium‑rich endolymphatic environment essential for transducing sound waves, leading to cellular apoptosis.
Primary causes
- Therapeutic use for malaria – Especially high‑dose regimens (e.g., intravenous quinine for severe malaria).
- Off‑label use for nocturnal leg cramps – Typically 200 mg to 500 mg 1–3 times daily, which can accumulate in susceptible individuals.
- Self‑medication or unsupervised use – Over‑the‑counter “quinine water” products may contain undisclosed amounts.
Risk factors
- Renal insufficiency or hepatic impairment (decreased clearance → higher plasma levels).
- Advanced age (>65 years).
- Concurrent ototoxic drugs (e.g., gentamicin, vancomycin, loop diuretics).
- Pre‑existing hearing loss or vestibular disease.
- Genetic polymorphisms affecting quinine metabolism (e.g., CYP3A4 variants).
- High cumulative dose (>2 g per day for more than 7 days).
Diagnosis
Prompt recognition hinges on a detailed medication history and focused otologic examination.
Clinical evaluation
- History – Document quinine dosage, route, duration, and timing of symptom onset.
- Physical otoscopy – Usually normal; helps rule out middle‑ear pathology.
- Neurological exam – Checks for vestibular involvement or cranial nerve deficits.
Audiologic testing
- Pure‑tone audiometry – Detects sensorineural loss, often beginning at 4–8 kHz.
- Speech‑in‑noise tests – Assess functional hearing impact.
- Otoacoustic emissions (OAEs) – Sensitive for early outer‑hair‑cell dysfunction before audiogram changes.
- Auditory brainstem response (ABR) – Evaluates neural transmission if central involvement is suspected.
Laboratory assessment
- Serum quinine level (if available) – Helps confirm supratherapeutic exposure.
- Renal and hepatic panels – Identify organ dysfunction that may exacerbate toxicity.
Imaging (rarely needed)
Magnetic resonance imaging (MRI) of the internal auditory canal may be ordered to exclude other causes of sudden hearing loss (e.g., vestibular schwannoma) when the diagnosis is uncertain.
Treatment Options
The cornerstone of management is immediate discontinuation of quinine, followed by supportive and, when appropriate, pharmacologic interventions.
1. Discontinue quinine
Stopping the offending agent usually halts progression. In severe malaria, alternative antimalarials (e.g., artesunate, artemisinin‑based combination therapy) should be initiated under specialist guidance.
2. Corticosteroids
High‑dose oral or intratympanic steroids are employed for sudden sensorineural hearing loss (SSNHL) to reduce inflammation and edema. Evidence is mixed, but a 10‑day prednisone taper (1 mg/kg) within 2 weeks of symptom onset improves outcomes in ~50 % of cases.3
3. Hyperbaric oxygen therapy (HBOT)
HBOT has shown modest benefit in SSNHL when started within 2 weeks, particularly for ototoxic etiologies. Sessions are typically 60–90 minutes at 2.0–2.5 ATA for 10–15 days.
4. Hearing rehabilitation
- Amplification devices – Hearing aids tailored to the residual frequency range.
- Cochlear implants – Considered for profound, permanent loss unresponsive to conventional amplification.
5. Lifestyle and supportive measures
- Protect ears from additional noise exposure (e.g., earplugs, limit volume).
- Maintain hydration and a low‑sodium diet to support renal clearance.
- Manage comorbidities (diabetes, hypertension) that can worsen auditory health.
Living with Quinine‑Induced Hearing Loss
Even after stabilization, many patients need strategies to adapt to changed hearing.
Communication tips
- Face the person speaking and maintain good lighting.
- Ask for clarification; request “repeat” instead of “sorry?”
- Use visual cues, written notes, or speech‑to‑text apps.
Environmental modifications
- Reduce background noise in home and workplace (carpets, curtains, soft furnishings).
- Install assistive listening systems in frequently used rooms (e.g., TV loop, amplified telephone).
- Choose smartphones with hearing‑aid compatibility and captioning features.
Regular follow‑up
Schedule audiology appointments every 6–12 months to monitor progression and adjust hearing devices. Report any new or worsening symptoms promptly.
Emotional well‑being
Hearing loss can lead to social isolation and depression. Seek counseling, support groups (e.g., Hearing Loss Association of America), or mental‑health professionals if needed.
Prevention
Because quinine‑related ototoxicity is dose‑dependent, prevention focuses on judicious prescribing and monitoring.
- Reserve quinine for proven indications (e.g., severe malaria) and avoid off‑label use for leg cramps.
- Adhere strictly to recommended dosage and duration; avoid self‑medication.
- Screen baseline hearing in high‑risk patients before initiating therapy.
- Monitor serum quinine levels when high‑dose regimens are necessary.
- Adjust dose for renal or hepatic impairment according to prescribing guidelines.
- Inform patients about early otologic warning signs and the need to stop the drug immediately if they occur.
Complications
If not recognized early, quinine‑induced ototoxicity can lead to:
- Permanent sensorineural hearing loss – Especially high‑frequency loss that impairs speech discrimination.
- Tinnitus chronicity – Persistent ringing that may affect sleep and concentration.
- Vestibular dysfunction – Chronic dizziness or imbalance, increasing fall risk.
- Psychosocial impact – Depression, anxiety, and reduced quality of life.
- Professional limitations – Especially in occupations requiring fine auditory discrimination (musicians, pilots, air traffic controllers).
When to Seek Emergency Care
- Sudden, severe hearing loss in one or both ears.
- Rapidly worsening tinnitus or a sensation of “fullness” that does not improve.
- Vertigo or loss of balance accompanied by nausea/vomiting.
- Signs of quinine toxicity beyond the ears – such as cardiac arrhythmias, severe headache, visual disturbances, or a drop in blood pressure.
References
- Mayo Clinic. “Quinine: Uses, Side Effects, and Precautions.” 2023. https://www.mayoclinic.org/quinine-oral-route/description/drg-20072011
- World Health Organization. “Guidelines for the treatment of malaria, 3rd edition.” 2022.
- American Academy of Otolaryngology–Head and Neck Surgery. “Clinical Practice Guideline: Sudden Hearing Loss.” 2021. https://www.entnet.org/resource/sudden-hearing-loss-guideline
- Cleveland Clinic. “Ototoxic Medications.” 2022. https://my.clevelandclinic.org/health/drugs/17647-ototoxic-drugs
- National Institutes of Health – National Institute on Deafness and Other Communication Disorders. “Understanding Hearing Loss.” 2023.